Literature DB >> 8557233

The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma.

E M Swisher1, A M Gown, M Skelly, M Ek, H K Tamimi, J M Cain, B E Greer, H G Muntz, B A Goff.   

Abstract

Uterine malignant mixed mesodermal tumors (MMMT) are highly malignant tumors containing both malignant glands and stroma, while adenosarcomas (AS) are less aggressive tumors composed of malignant stroma and benign glands. Immunohistochemistry was used to grade overexpression of p53 protein, HER-2/neu protein, epidermal growth factor receptor (EGFR), and Ki-67 antigen in both the glands and stroma of tissue from 20 women with MMMT and 6 women with AS. EGFR was overexpressed in 2 AS and 9 MMMT, and was more commonly found in the sarcomatous component than the carcinomatous component in MMMT (P = 0.03). p53 was not found in any AS samples and was strongly present in 6 MMMT samples with a random distribution between the malignant components. HER-2/neu protein was not overexpressed in any AS or primary MMMT. Ki-67 antigen, a marker of cell proliferation, was found at higher levels in MMMT than AS samples (P = 0.03) and high Ki-67 antigen expression correlated with a decreased survival in patients with MMMT (P = 0.004). Independent characterization of oncogene proteins in the malignant components of these heterogeneous tumors may provide insight into the histogenesis and behavior of these malignancies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8557233     DOI: 10.1006/gyno.1996.0015

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma.

Authors:  Gloria S Huang; Lydia G Chiu; Juliana S Gebb; Marc J Gunter; Paniti Sukumvanich; Gary L Goldberg; Mark H Einstein
Journal:  Gynecol Oncol       Date:  2007-10-23       Impact factor: 5.482

2.  Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy.

Authors:  Hiroshi Yoshida; Tadaaki Nishikawa; Koji Matsumoto; Masahiko Mori; Yasuyuki Hirashima; Kazuhiro Takehara; Kazuya Ariyoshi; Kosei Hasegawa; Kan Yonemori
Journal:  Virchows Arch       Date:  2021-01-09       Impact factor: 4.064

3.  Serous carcinomatous component championed by heparin-binding EGF-like growth factor (HB-EGF) predisposing to metastasis and recurrence in stage I uterine malignant mixed mullerian tumor.

Authors:  Lei Zhang; David Shimizu; Jeffrey L Killeen; Stacey A Honda; Di Lu; Alexander Stanoyevitch; Fritz Lin; Beverly Wang; Edwin S Monuki; Michele Carbone
Journal:  Hum Pathol       Date:  2016-03-11       Impact factor: 3.466

Review 4.  Uterine Adenosarcoma: a Review.

Authors:  Michael J Nathenson; Vinod Ravi; Nicole Fleming; Wei-Lien Wang; Anthony Conley
Journal:  Curr Oncol Rep       Date:  2016-11       Impact factor: 5.075

5.  Malignant mixed Mullerian tumors of the uterus: histopathological evaluation of cell cycle and apoptotic regulatory proteins.

Authors:  Rani Kanthan; Jenna-Lynn B Senger; Dana Diudea
Journal:  World J Surg Oncol       Date:  2010-07-19       Impact factor: 2.754

6.  Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma.

Authors:  Yong Hannah Wen; Edi Brogi; Adnan Hasanovic; Marc Ladanyi; Robert A Soslow; Dhananjay Chitale; Jinru Shia; Andre L Moreira
Journal:  Mod Pathol       Date:  2013-04-19       Impact factor: 7.842

7.  Uterine carcinosarcomas (malignant mixed müllerian tumours): a review with special emphasis on the controversies in management.

Authors:  Rani Kanthan; Jenna-Lynn Senger
Journal:  Obstet Gynecol Int       Date:  2011-10-05

8.  Inter-component immunohistochemical assessment of proliferative markers in uterine carcinosarcoma.

Authors:  Andrzej Pyra; Aneta Adamiak-Godlewska; Dorota Lewkowicz; Beata Bałon; Marek Cybulski; Anna Semczuk-Sikora; Andrzej Semczuk
Journal:  Oncol Lett       Date:  2022-08-31       Impact factor: 3.111

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.